Thus, the overall impact of a positive genetic testing for CDKN2A/CDK4 in the early detection and improved outcome of internal cancers and, in particular, of pancreatic cancer remains undetermined. The gene discussed is CDK4; the disease is familial pancreatic carcinoma.